Blueprint Medicines Touts 4-Year Drug Data
Blueprint Medicines, a Sanofi company, announced new four-year data for its drug AYVAKIT at the 2026 AAAAI Annual Meeting. The data shows sustained benefits and long-term safety for patients with Indolent Systemic Mastocytosis, a rare hematologic disorder.
Indolent Systemic Mastocytosis (ISM) is a rare blood disorder where the body produces too many mast cells. In about 95% of cases, the disease is driven by a mutation in the KIT D816V gene. Patients often experience a wide range of debilitating symptoms, including skin lesions, severe itching, flushing, abdominal pain, diarrhea, bone pain, and brain fog. The unpredictable nature of these symptoms can significantly impair a person's quality of life, making it difficult to maintain work and social activities. The burden of ISM has been found to be comparable to that of serious conditions like lymphoma and leukemia. Some individuals "live in a bubble" to avoid triggers that can provoke severe reactions, including life-threatening anaphylaxis. Prior to AYVAKIT's approval, treatment for ISM was limited to managing symptoms with a combination of medications such as H1 and H2 antihistamines, leukotriene antagonists, and corticosteroids. These therapies did not address the underlying cause of the disease, and for many patients, symptoms remained inadequately controlled. The approval of AYVAKIT (avapritinib) by the FDA on May 22, 2023, marked a significant shift in the treatment paradigm for ISM, making it the first and only approved therapy for this condition. The approval was based on the results of the PIONEER clinical trial. The PIONEER trial demonstrated that AYVAKIT provided statistically significant and clinically meaningful improvements in patients' total symptom scores compared to a placebo. At 24 weeks, patients taking AYVAKIT experienced a 15.6-point reduction in their mean total symptom score, which deepened to a 20.2-point reduction at 48 weeks. AYVAKIT is a targeted therapy that potently and selectively inhibits the KIT D816V mutation, the primary driver of ISM. By targeting the root cause of the disease, the drug reduces the abnormal mast cell burden, leading to symptom improvement. In early 2025, Sanofi announced its acquisition of Blueprint Medicines, the developer of AYVAKIT. This acquisition brings the targeted therapy into the portfolio of a major pharmaceutical company, potentially expanding its reach to more patients. Ongoing research and long-term data from the PIONEER study continue to show the sustained benefits and safety of AYVAKIT. Future research may explore the use of avapritinib earlier in the disease course to potentially prevent the development of severe symptoms. Other KIT inhibitors are also in clinical trials, offering hope for more treatment options in the future.
